NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ:INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors […]

NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ:RZLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Rezolute and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nektar and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Anavex and certain of its officers and/or

NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ:OM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Outset Medical and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ:WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Waldencast and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Aerovironment, Inc. ("Aerovironment" or the "Company") (NASDAQ:AVAV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aerovironment and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether RxSight and certain of its officers and/or directors have

NEW YORK CITY, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE:GPK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Graphic Packaging and certain of

NEW YORK CITY, NY / ACCESS Newswire / January 3, 2026 / Pomerantz LLP is investigating claims on behalf of investors of SCHMID Group N.V. ("Schmid" or the "Company") (NASDAQ:SHMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Schmid and certain of its officers and/or